Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer

Müller, Martin C.; Güth, Uwe; Varga, Zsuzsanna; Reeve, Kelly; Bjelic‐Radisic, Vesna; Fleisch, Markus; Tausch, Christoph; Elfgen, Constanze

doi:10.21873/anticanres.14171

Cited by 6 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most prevalent circumstance of discovery, in 90% of cases of our series, was the palpation of a breast nodule, this result is consistent with literature data [12]. In 61% of instances, the nodule was found in the upper external quadrant, whereas 47% were found in the posterior third of the breast [13].…”

Section: Triple-negative Breast Cancer Is Distinguished By No Estroge...supporting

confidence: 92%

Evolutionary Profil of Triple-Negative Breast Cancer and Influence of Histopronostic Factors: Experience of Oncology Department Chu Ibn Rochd Casablanca

Kabala,

Bourhafour,

Chekrine

et al. 2023

EJMED

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a subgroup of breast cancer with hormone receptor and Her2 overexpression absence, accounting for 15%–20% of all breast cancers. Its unpredictable evolution, poor treatment response, and highly invasive nature warrant research interest. The main objective of this study is to assess the evolution of triple-negative breast cancer as a role for histopronostic factors. We present the evolutionary profile of triple-negative breast cancer in the role of histopronostic factors using data from a four-year retrospective study of cases of triple-negative breast cancer collected in the oncology-radiotherapy department at Chu Ibn Rochd Casablanca between January 2015 and December 2019. 232 patients were included, regardless of disease stage. The mean age was 49.54 ± 11.21 years. In 68% of cases, the disease was localized. All metastatic patients (32%) died, with a median survival of 15 months. We analyzed the evolution of triple-negative breast cancer in localized disease as a role for age, tumor size, histological type, SBR grade, lymph node invasion, and vascular invasion, with a median follow-up of 24 months (2 years). In 158 patients in our series with localized disease, local or locoregional recurrence was noted in 16% of cases, metastatic relapse in 10%, and 30% of cases were still in complete remission. Patients aged between 40 and 50 had a higher rate of local and locoregional recurrence. Patients with tumors between 2 and 6 cm in size had a high rate of metastasis and death. Grade SBR III is generally marked by a poor prognosis, with 39 patients having local or locoregional recurrence, 41 patients having metastases, and 15 patients having died. In our series, the greater the lymph node and vascular invasion, the poorer the prognosis, with a higher risk of recurrence and metastasis. These results support the role of early screening, especially for at-risk patients, adequate therapeutic management, and active surveillance of patients with triple-negative breast cancer. New research has shown the effectiveness of immune checkpoint inhibitors and anti-parp in treating advanced triple-negative breast cancer (TNBC), with encouraging findings indicating their potential benefit. Clinical studies including anatomical pathologists, oncologists, and fundamental researchers must be conducted globally to achieve this. Clinical studies involving pathologists, oncologists, and basic researchers are needed worldwide to define new therapeutic strategies for the management of this type of aggressive breast cancer.

show abstract

Section: Triple-negative Breast Cancer Is Distinguished By No Estroge...supporting

confidence: 92%

Evolutionary Profil of Triple-Negative Breast Cancer and Influence of Histopronostic Factors: Experience of Oncology Department Chu Ibn Rochd Casablanca

Kabala,

Bourhafour,

Chekrine

et al. 2023

EJMED

View full text Add to dashboard Cite

show abstract

“…A recent study analyzing the correlations between AR expression and age revealed higher levels of AR tumors in older and postmenopausal patients than in younger and premenopausal patients [56]. Muller et al observed that in LAR-TNBC, the lesions typically appear as spiculated margins (24.3% vs. 0-4.1% in other subtypes) or mammographic calcifications (8.1%) [57,58]. AR-positive tumors are highly differentiated tumors with low Ki-67 expression that display an irregular shape, which accounts for their low proliferation rate [59].…”

Section: The Biological Role Of Androgen Receptormentioning

confidence: 99%

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer

Khadela

Chavda

Soni

et al. 2022

Cancers

View full text Add to dashboard Cite

Triple-negative tumors are progressively delineating their existence over the extended spectrum of breast cancers, marked by intricate molecular heterogeneity, a low overall survival rate, and an unexplored therapeutic approach. Although the basal subtype transcends the group and contributes approximately 80% to triple-negative breast cancer (TNBC) cases, the exceptionally appearing mesenchymal and luminal androgen receptor (LAR) subtypes portray an unfathomable clinical course. LAR with a distinct generic profile frequently metastasizes to regional lymph nodes and bones. This subtype is minimally affected by chemotherapy and shows the lowest pathologic complete response. The androgen receptor is the only sex steroid receptor that plays a cardinal role in the progression of breast cancers and is typically overexpressed in LAR. The partial AR antagonist bicalutamide and the next-generation AR inhibitor enzalutamide are being assessed in standard protocols for the mitigation of TNBC. There arises an inevitable need to probe into the strategies that could neutralize these androgen receptors and alleviate the trajectory of concerning cancer. This paper thus focuses on reviewing literature that provides insights into the anti-androgenic elements against LAR typical TNBC that could pave the way for clinical advancements in this dynamic sphere of oncology.

show abstract

Deep self-reconstruction driven joint nonnegative matrix factorization model for identifying multiple genomic imaging associations in complex diseases

Deng,

Wei,

Fang

et al. 2024

Journal of Biomedical Informatics

View full text Add to dashboard Cite

Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer

Cited by 6 publications

References 20 publications

Evolutionary Profil of Triple-Negative Breast Cancer and Influence of Histopronostic Factors: Experience of Oncology Department Chu Ibn Rochd Casablanca

Evolutionary Profil of Triple-Negative Breast Cancer and Influence of Histopronostic Factors: Experience of Oncology Department Chu Ibn Rochd Casablanca

Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer

Deep self-reconstruction driven joint nonnegative matrix factorization model for identifying multiple genomic imaging associations in complex diseases

Contact Info

Product

Resources

About